Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.60 |
| ▸ | RAB9A | P51151 | 6/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4090449 | 0.83 | GSTO1 (0.51) | MAPTRAB9ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL1435582 | 0.77 | RAB9A (0.55) | MAPTRAB9ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL4732495 | 0.76 | MAPT (0.56) | MAPTRAB9ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL7472306 | 0.76 | MAPT (1.00) | MAPTRAB9ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL4797546 | 0.75 | RAB9A (0.55) | MAPTRAB9ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL4780726 | 0.74 | MAPT (0.53) | MAPTRAB9ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL4799462 | 0.74 | RAB9A (0.56) | MAPTRAB9ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL11491739 | 0.72 | MAPT (0.67) | MAPTRAB9ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL8293261 | 0.71 | MAPT (0.62) | MAPTRAB9ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL4799172 | 0.71 | MAPT (0.49) | MAPTRAB9ASMN1; SMN2ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203747-A1 | NOVEL CHEMICAL COMPOUNDS AND THE USES THEREOF AS A MEDICINE | TROPHOS PARC SCIENTIFIQUE LUMINY (FR) | 2009-08-13 | — | — | US | claimed |
| US-20090203747-A1 | NOVEL CHEMICAL COMPOUNDS AND THE USES THEREOF AS A MEDICINE | TROPHOS PARC SCIENTIFIQUE LUMINY (FR) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203747-A1 | NOVEL CHEMICAL COMPOUNDS AND THE USES THEREOF AS A MEDICINE | NLN, NQO1, APP | MAPT 31/4885RAB9A 2239/4885SMN1; SMN2 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.